SecurityGSK / GlaxoSmithKline plc
InstitutionBerkeley Capital Partners, LLC
Shares8,460
Value $ 341,000
Related 377372AG2 / Glaxosmithkline Cap Inc. 0.70% 03/18/16
377372AH0 / Glaxosmithkline Cap Inc. 2.80% 03/18/23
377372AJ6 / Glaxosmithkline Cap Inc. 4.20% 03/18/43
377372AA5 / Glaxosmithkline Cap Inc Guaranteed Notes 4.375% 04/15/14
377372AB3 / Glaxosmithkline Cap Inc Guaranteed Notes 5.375% 04/15/34
377373AC9 / Glaxosmithkline Capital 1.50% 05/08/17
377373AD7 / Glaxosmithkline Capital 2.85% 05/08/22
377372AC1 / Glaxosmithkline Capital 4.85% Guaranteed Notes 5/15/13
377372AD9 / Glaxosmithkline Capital 5.65% Guaranteed Notes 5/15/18
377372AE7 / Glaxosmithkline Capital 6.375% Guaranteed Notes 5/15/38
377373AB1 / Glaxosmithkline Capital .75% 05/08/15

Berkeley Capital Partners, LLC reports 18.43% decrease in ownership of GSK / GlaxoSmithKline plc

August 07, 2018 - Berkeley Capital Partners, LLC has filed a 13F-HR form disclosing ownership of 8,460 shares of GlaxoSmithKline plc (NYSE:GSK) with total holdings valued at $341,000 USD as of June 30, 2018. Berkeley Capital Partners, LLC had filed a previous 13F-HR on April 27, 2018 disclosing 10,372 shares of GlaxoSmithKline plc at a value of $405,000 USD. This represents a change in shares of -18.43 percent and a change in value of -15.80 percent during the quarter.

Other investors with positions similar to Berkeley Capital Partners, LLC include Bremer Trust National Association, Ridgewood Investments LLC, Landmark Bank, First Financial Bank, N.A. - Trust Division, NEXT Financial Group, Inc, and Poplar Forest Capital LLC.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR Glaxosmithkline SPONSORED ADR 37733W105 39.68 8,460 -18.43 341 -15.80 -76 12 2.93
2018-03-31 13F-HR Glaxosmithkline SPONSORED ADR 37733W105 37.26 10,372 -16.56 405 -8.16 -77 41 9.23
2017-12-31 13F-HR Glaxosmithkline SPONSORED ADR 37733W105 38.05 12,430 -3.28 441 -15.52 -16 -65 -12.45
2017-09-30 13F-HR Glaxosmithkline SPONSORED ADR 37733W105 41.88 12,851 73.78 522 63.64 228 -25 -7.99
2017-06-30 13F-HR Glaxosmithkline SPONSORED ADR 37733W105 42.67 7,395 -11.08 319 -9.12 -39 7 2.08
2017-03-31 13F-HR Glaxosmithkline SPONSORED ADR 37733W105 40.37 8,316 -38.01 351 -32.11 -206 40 7.72
2016-12-31 13F-HR GLAXOSMITHKLINE SPONSORED ADR 37733W105 40.85 13,416 75.51 517 56.67 236 -49 -14.79
2016-09-30 13F-HR GLAXOSMITHKLINE SPONSORED ADR 37733W105 43.27 7,644 1.37 330 0.92 4 -1 -0.45
2016-06-30 13F-HR Glaxosmithkline SPONSORED ADR 37733W105 41.96 7,541 -32.79 327 -28.13 -154 26 5.79
2016-03-31 13F-HR Glaxosmithkline SPONSORED ADR 37733W105 40.47 11,220 64.20 455 64.86 178 1 0.52
2015-12-31 13F-HR GLAXOSMITHKLINE SPONSORED ADR 37733W105 6,833 276


CUSIP: 37733W105